In line with its physiological immunosuppressive role, it could be shown that MPN patients have increased levels of Arginase-1 expressing MDSCs, thereby pathophysiologically suppressing the anti-leukemia immune response in these patients [98]. This evidence concerns the gene ARG1 and myeloproliferative disorder.